`Worldwide Net Sales of Competitor Drugs
`
`Brand
`
`Januvia
`
`Janumet
`
`Total
`
`Drug
`
`Sitagliptin
`
`Vildagliptin
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Total
`
`
`
`43$
`
`
`
`668$
`
`
`
`1,397$
`
`
`
`1,922$
`
`
`
`2,385$
`
`
`
`3,324$
`
`
`
`4,086$
`
`
`
`4,004$
`
`
`
`3,931$
`
`
`
`3,863$
`
`
`
`25,623$
`
`Total
`2009 - 2015
`
`23,515$
`
`n/a
`
`
`
`86$
`
`
`
`351$
`
`
`
`658$
`
`
`
`954$
`
`
`
`1,363$
`
`
`
`1,659$
`
`
`
`1,829$
`
`
`
`2,071$
`
`
`
`2,151$
`
`
`
`11,123$
`
`
`
`10,685$
`
`
`
`43$
`
`
`
`754$
`
`
`
`1,748$
`
`
`
`2,580$
`
`
`
`3,339$
`
`
`
`4,687$
`
`
`
`5,745$
`
`
`
`5,833$
`
`
`
`6,002$
`
`
`
`6,014$
`
`
`
`36,745$
`
`
`
`34,200$
`
`
`
`5,723$
`
`Galvus/Eucreas
`(Non-US only)
`
`US
`
`Non-US
`
`Total
`
`n/a
`
`n/a
`
`n/a
`
`n/a
`
`Saxagliptin
`
`n/a
`
`
`
`43$
`
`
`
`181$
`
`
`
`391$
`
`
`
`677$
`
`
`
`910$
`
`
`
`1,200$
`
`
`
`1,224$
`
`
`
`1,140$
`
`
`
`5,766$
`
`n/a
`
`n/a
`
`n/a
`
`n/a
`
`n/a
`
`n/a
`
`
`
`22$
`
`
`
`119$
`
`
`
`339$
`
`
`
`516$
`
`
`
`591$
`
`
`
`481$
`
`
`
`420$
`
`
`
`2,488$
`
`
`
`2,488$
`
`
`
`2$
`
`
`
`39$
`
`
`
`134$
`
`
`
`193$
`
`
`
`286$
`
`
`
`339$
`
`
`
`366$
`
`
`
`1,359$
`
`
`
`1,359$
`
`
`
`24$
`
`
`
`158$
`
`
`
`473$
`
`
`
`709$
`
`
`
`877$
`
`
`
`820$
`
`
`
`786$
`
`
`
`3,847$
`
`
`
`3,847$
`
`Notes and sources:
`Figures are in millions of USD.
`Sitagliptin: EX1052 at 8, 59; EX1054 at 7, 54; EX1056 at 6, 50; EX1059 at 3, 43, 68, 132; see also EX1053 EX1055 EX1057-EX1059.
`Vildagliptin: EX1045 at 266; EX1046 at 140; EX1047 at 137; EX1048 at 114; EX1049 at 147; EX1050 at 113, 115; EX1051 at 189; see also EX1044.
`Saxagliptin: EX 2113 at 35, EX 2113 at 35, EX 2113 at 35, EX 2115 at 35, EX 2115 at 35, EX 2004 at 203, EX 2108 at 210, 228.
`
`Attachment B-1a
`Page 1 of 14
`
`MYLAN - EXHIBIT 1062
`Mylan et al. v. AstraZeneca
`IPR2015-01340
`
`
`
`Attachment B-1b
`
`Chart of Sitagliptin, Vildagliptin, and Saxagliptin Worldwide Net Sales
`
`$7.000
`
`$6.000
`.2a
`
`$5,000
`
`$4,000
`
`3,000
`‘ T
`
`$2,000
`
`’”°° j.._.
`
`5-
`
`2009
`
`2010
`
`2011
`
`2012
`
`Year
`
`2013
`
`2014
`
`2015
`
`Notes and soumes:
`
`Attachment B-la
`
`Tsitagliptin :Vi|dag|iptin jSaxag|iptin
`
`
`
`Attachment B-1c
`
`Chart of Vildagliptin and Saxagliptin Net Sales
`
`$1,400
`
`$1’
`
`$1,000
`
`E’E’
`
`$200
`
`5-
`
`2009
`
`Notes and sources:
`
`Attachment B-la
`
`{L
`
`2010
`
`2011
`
`2012
`
`Year
`
`2013
`
`2014
`
`2015
`
`TVi|dag|iptin (Non—US)
`
`isaxagliptin (Total)
`
`jsaxagliptin (Non—US)
`
`
`
`Attachment B-2
`
`Attachment B-2
`Page 4 of 14
`
`
`
`Attachment B-3
`
`Attachment B-3
`Page 5 of 14
`
`
`
`Attachment B-4
`
`Attachment B-4
`Page 6 of 14
`
`
`
`Attachment B-5
`
`Attachment B-5
`Page 7 of 14
`
`
`
`Attachment B-6
`
`Attachment B-6
`Page 8 of 14
`
`
`
`Attachment B-7
`
`Attachment B-7
`Page 9 of 14
`
`
`
`Attachment B-8a
`
`Attachment B-8a
`Page 10 of 14
`
`
`
`Attachment B-8b
`
`Attachment B-8b
`Page 11 of 14
`
`
`
`Attachment B-9
`Novartis Net Sales Adjustment
`
`Measure
`
`Gross sales
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Total
`
`
`
`33,010$
`
`
`
`36,400$
`
`
`
`40,004$
`
`
`
`39,912$
`
`
`
`40,188$
`
`
`
`39,529$
`
`
`
`37,853$
`
`
`
`266,896$
`
`Adjustment to net sales
`
`
`
`(4,723)$
`
`
`
`(6,094)$
`
`
`
`(7,496)$
`
`
`
`(7,759)$
`
`
`
`(7,974)$
`
`
`
`(7,739)$
`
`
`
`(7,408)$
`
`
`
`(49,193)$
`
`Net sales
`
`
`
`28,287$
`
`
`
`30,306$
`
`
`
`32,508$
`
`
`
`32,153$
`
`
`
`32,214$
`
`
`
`31,790$
`
`
`
`30,445$
`
`
`
`217,703$
`
`Net sales adjustment
`
`-14.3%
`
`-16.7%
`
`-18.7%
`
`-19.4%
`
`-19.8%
`
`-19.6%
`
`-19.6%
`
`-18.4%
`
`Notes and sources:
`Figures are in millions of USD.
`Similar information not available for Merck (sitagliptin).
`2009-2011: EX1047: Novartis, Form 20-F, 2011, at 121.
`2012-2013: EX1049: Novartis, Annual Report, 2013, at 166.
`2014-2015: EX1051: Novartis, Annual Report, 2015, at 159.
`
`Attachment B-9
`Page 12 of 14
`
`
`
`Attachment B-10a
`
`Attachment B-10a
`Page 13 of 14
`
`
`
`Attachment B-10b
`
`Attachment B-10b
`Page 14 of 14